CRB Taps John Lupa to Lead Construction Amid Biopharma & F&B Boom

📊 Key Data
  • 8-10%: Projected compound annual growth rate for the biopharmaceutical sector over the next five years.
  • $500 million: Capital investment program John Lupa oversaw at Lonza Biologics' Vacaville facility.
  • 21 offices: Number of CRB offices nationwide where Lupa will reinforce consistency.
🎯 Expert Consensus

Experts would likely conclude that CRB's appointment of John Lupa strengthens its position to capitalize on the booming biopharma and F&B sectors, leveraging his extensive experience to deliver complex, large-scale projects with greater efficiency and integration.

2 months ago
CRB Taps John Lupa to Lead Construction Amid Biopharma & F&B Boom

CRB Taps John Lupa to Lead Construction Amid Biopharma & F&B Boom

Kansas City, MO – February 12, 2026 – In a significant move to bolster its construction capabilities, CRB has appointed industry veteran John R. Lupa, Jr. as its new Vice President, National Construction. The appointment signals a strategic intensification of the firm's focus on delivering large-scale, complex facilities for the burgeoning life sciences and food and beverage industries. Lupa, with over three decades of experience managing multi-billion-dollar capital programs, joins CRB as the company aims to solidify its leadership in a rapidly evolving market.

A Strategic Play to Capture Market Growth

Lupa's appointment is a cornerstone of CRB's 2026 strategic plan, a forward-looking initiative designed to deliver “greater project certainty, faster execution of complex programs, and a more integrated and scalable construction offering.” This strategy is a direct response to powerful market currents. The biopharmaceutical sector, for instance, is projected to grow at a compound annual rate of 8-10% over the next five years, fueling unprecedented demand for advanced manufacturing facilities.

This demand is not just for more space, but for highly specialized environments capable of supporting cell and gene therapies, advanced biologics, and other next-generation treatments. Following a period of recalibration, venture capital funding in biopharma has rebounded, driving new investments in domestic manufacturing. This creates a fertile environment for firms like CRB that possess deep technical expertise.

Simultaneously, the food and beverage industry is undergoing its own transformation, with companies investing heavily in modernizing facilities to enhance automation, improve food safety, and increase efficiency. CRB's leadership clearly sees the opportunity in these parallel booms. “John’s experience and leadership will play an important role as we continue to strengthen how we deliver complex projects for our clients,” said Vahid Ownjazayeri, President and CEO of CRB. “He understands what it takes to execute at scale – safely, efficiently, and with discipline – and he brings a practical, people-first approach that aligns well with CRB’s culture and long-term strategy.”

The Master Builder: A Career Forged in Complexity

John R. Lupa, Jr. brings a resume built on managing the kind of high-stakes projects that define modern industrial construction. His career is a testament to expertise across the entire project lifecycle, from initial planning and design through construction, commissioning, and final turnover. This holistic understanding is critical for mitigating risk and increasing predictability on projects where schedules and budgets are paramount.

Prior to joining CRB, Lupa served as Senior Director of Global Engineering, Planning & Project Controls at Lonza Biologics. In this role, he was instrumental in leading major manufacturing expansions. Notably, he oversaw a $500 million capital investment program at the large-scale mammalian facility in Vacaville, California, which Lonza acquired from Genentech. This project was a key part of Lonza’s strategy to boost its manufacturing capacity for high-volume monoclonal antibody treatments.

His track record for handling massive projects was honed during more than a decade with Fluor Corporation, a global engineering and construction giant. As an EPC Project Director, he helped shape execution strategies for projects exceeding $1 billion in total value. His extensive career also includes significant engineering and construction leadership roles at industry titans such as Pfizer, Wyeth Pharmaceuticals, and Duke Energy, giving him a uniquely broad perspective across the life sciences and energy sectors. Lupa’s academic credentials, including an M.B.A. and an M.S. in Business Analytics and Risk Management from The Johns Hopkins University, complement his extensive field experience.

Integrating Design and Delivery for Next-Gen Facilities

In his new capacity, Lupa is tasked with a clear mission: expand CRB’s national construction capabilities, reinforce consistency across the company’s 21 offices, and tighten the alignment between design, construction, and commissioning teams. This focus on integration is central to the company’s value proposition.

This approach directly enhances CRB’s proprietary “ONEsolution™” project delivery method. This integrated model brings a single, unified team to a project from its inception, a structure designed to maximize value and reduce the risks inherent in the traditional, siloed approach to design and construction. Lupa’s deep experience in leading cross-functional teams on Engineering, Procurement, and Construction (EPC) projects makes him a natural fit to champion and scale this model.

For clients, the practical impact is significant. In an era where speed-to-market is a critical competitive advantage, particularly for pharmaceutical companies launching new therapies, a more integrated and predictable construction process can translate into millions of dollars in revenue. By strengthening the connection between the architects who design a facility and the teams who build it, CRB aims to deliver the advanced, compliant, and efficient facilities its clients need, faster and with greater certainty.

Fortifying a Competitive Edge in a Specialized Market

CRB already holds a formidable position in its niche markets. The company is consistently ranked by Engineering News-Record as a top-tier provider, including #2 for pharmaceutical manufacturing design and #8 for food and beverage services. However, the appointment of Lupa is a clear signal that the company is not resting on its laurels.

Hiring a leader directly from a major client like Lonza and a top competitor like Fluor is a strategic power play. It brings invaluable perspective on client needs and competitor strategies directly into CRB’s leadership team. This move equips CRB to compete more aggressively for the largest and most technically demanding projects, where clients demand a partner who can manage immense complexity and guarantee outcomes.

The market for building advanced manufacturing facilities has moved beyond simple construction. Clients are seeking end-to-end partners who can provide strategic advice, navigate complex regulatory landscapes, and deliver a fully operational asset that aligns with their core business goals. By placing a proven leader like John Lupa at the helm of its national construction efforts, CRB is making a definitive statement that it is prepared to be that partner, ready to build the critical infrastructure for the future of life sciences and food production.

Product: AI & Software Platforms
Sector: Biotechnology Food & Beverage Pharmaceuticals Construction
Theme: Venture Capital
UAID: 15598